Samsung Bioepis Reports the EC Launch of Opuviz (Biosimilar, Eylea)

Why It Matters

Introducing a lower‑cost aflibercept biosimilar strengthens price competition in the EU ophthalmology market, potentially improving patient access to high‑priced anti‑VEGF therapies.

Key Takeaways

• Opuviz 40 mg/mL vial launches across EU this month.
• Biosimilar targets wet AMD, DME, RVO, myopic CNV.
• Samsung Bioepis will commercialize directly, bypassing partners.
• CHMP approved pre‑filled syringe, slated for Q3 2026 release.
• Entry adds price pressure to Eylea market.

Pulse Analysis

The anti‑VEGF drug aflibercept, sold as Eylea, has dominated the European market for retinal diseases, commanding premium pricing that strains healthcare budgets. As the first biosimilar from Samsung Bioepis, Opuviz leverages the company’s robust biologics platform and its experience scaling biosimilar launches in other therapeutic areas. By offering a 40 mg/mL vial formulation, the firm targets ophthalmologists seeking a familiar dosing regimen while anticipating cost savings that could drive formulary inclusion across national health systems.

Regulatory clearance for Opuviz’s vial came through the European Commission, while the Committee for Medicinal Products for Human Use (CHMP) issued a favorable opinion on a pre‑filled syringe version in November 2025. Samsung Bioepis’s decision to commercialize the product directly, rather than partnering with a regional distributor, signals confidence in its sales infrastructure and a desire to capture higher margins. The dual‑device strategy—vial for existing infusion practices and syringe for streamlined administration—positions Opuviz to meet diverse clinical preferences and accelerate uptake in ophthalmology clinics.

The launch intensifies competition against Roche’s Eylea, which has faced mounting pressure from other biosimilars entering the market. Price erosion is expected as payers negotiate rebates and hospitals adopt Opuviz to manage budget impact. For patients, increased competition may translate into broader access to life‑changing vision‑preserving therapy. Looking ahead, Samsung Bioepis’s success could encourage further biosimilar entries in the high‑growth retinal‑disease segment, reshaping the European ophthalmic landscape over the next decade.